BR0206521A - Misturas de enzimas microbianas - Google Patents

Misturas de enzimas microbianas

Info

Publication number
BR0206521A
BR0206521A BR0206521-5A BR0206521A BR0206521A BR 0206521 A BR0206521 A BR 0206521A BR 0206521 A BR0206521 A BR 0206521A BR 0206521 A BR0206521 A BR 0206521A
Authority
BR
Brazil
Prior art keywords
pharmaceutical preparations
microbial
microbial enzyme
mixtures
poor digestion
Prior art date
Application number
BR0206521-5A
Other languages
English (en)
Inventor
Manfred Galle
Peter-Colin Gregory
Andreas Potthoff
Friederike Henniges
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10144711A external-priority patent/DE10144711A1/de
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Priority to ARP030104319A priority Critical patent/AR042124A1/es
Priority to UY28088A priority patent/UY28088A1/es
Publication of BR0206521A publication Critical patent/BR0206521A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MISTURAS DE ENZIMAS MICROBIANAS". São descritas novas misturas de enzimas microbianas que contêm uma lipase concentrada de Rhizopus delemar e adicionalmente uma protease de Aspergillus melleus, bem como uma amilase de Aspergilius otyzae. Para além disso, são descritas preparações farmacêuticas que contêm estas misturas de enzimas microbianas. As novas preparações farmacêuticas são particularmente bem adequadas para o tratamento e/ou profilaxia da má digestão, particularmente da má digestão que se baseia na insuficiência pancreática, em mamíferos e no ser humano.
BR0206521-5A 2001-01-19 2002-01-16 Misturas de enzimas microbianas BR0206521A (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP030104319A AR042124A1 (es) 2002-01-16 2003-11-21 Dispositivos para descarga y salida aplicados al retrete sanitario mejorado
UY28088A UY28088A1 (es) 2002-01-16 2003-11-21 Dispositivos para descarga y salida aplicados al retrete sanitario mejorado

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10102495 2001-01-19
DE10144711A DE10144711A1 (de) 2001-01-19 2001-09-11 Neue Gemische mikrobieller Enzyme
PCT/EP2002/000374 WO2002060474A2 (de) 2001-01-19 2002-01-16 Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion

Publications (1)

Publication Number Publication Date
BR0206521A true BR0206521A (pt) 2004-02-17

Family

ID=26008287

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206521-5A BR0206521A (pt) 2001-01-19 2002-01-16 Misturas de enzimas microbianas

Country Status (17)

Country Link
US (1) US20040057944A1 (pt)
EP (1) EP1381386A2 (pt)
JP (1) JP2004524838A (pt)
CN (1) CN1236817C (pt)
AR (1) AR032392A1 (pt)
BR (1) BR0206521A (pt)
CA (1) CA2434808A1 (pt)
CZ (1) CZ20031900A3 (pt)
HU (1) HUP0500560A3 (pt)
IL (1) IL157004A0 (pt)
MX (1) MXPA03005960A (pt)
NO (1) NO20033261D0 (pt)
NZ (1) NZ527148A (pt)
PL (1) PL362646A1 (pt)
RU (1) RU2003124078A (pt)
SK (1) SK9292003A3 (pt)
WO (1) WO2002060474A2 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
KR20060127857A (ko) * 2003-10-29 2006-12-13 알투스 파마슈티컬스 인코포레이티드 혈장 콜레시스토키닌(ｃｃｋ) 농도 조절 및 통증 치료를위한 비-췌장 프로테아제
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
DK1755656T3 (da) 2004-05-24 2010-10-04 Novozymes As Enzymer til farmaceutisk anvendelse
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
PT1809320E (pt) * 2004-10-14 2010-10-25 Altus Pharmaceuticals Inc Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática
NZ563777A (en) * 2005-06-24 2010-08-27 Novozymes As Serine protease derived from Bacillus licheniformis optionally in combination with lipases and amylases for pharmaceutical use
CN101208429A (zh) * 2005-06-24 2008-06-25 诺维信公司 用于药物用途的脂肪酶
AU2006261444A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Amylases for pharmaceutical use
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
WO2007020260A2 (en) * 2005-08-15 2007-02-22 Solvay Pharmaceuticals Gmbh Pancreatin micropellet cores suitable for enteric coating
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20100196344A1 (en) * 2005-10-14 2010-08-05 Cystic Fibrosis Foundation Therapeutics, Inc. Compositions and methods for treating pancreatic insufficiency
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20080081035A1 (en) * 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
US7998476B2 (en) 2006-11-22 2011-08-16 Standard Biologics, Inc. Method of treatment using Aspergillus oryzae protease
KR20090101930A (ko) 2006-12-21 2009-09-29 노보자임스 에이/에스 약학적 사용을 위한 리파아제 변형체
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
US8246950B2 (en) * 2007-02-20 2012-08-21 Aptalis Pharma Limited Stable digestive enzyme compositions
US20090068174A1 (en) * 2007-09-12 2009-03-12 Kansas University Medical Center Research Institute, Inc. Therapeutic alkaline protease compositions and use in facilitating the transport of agents across the gastrointestinal mucosal lining
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US8455235B2 (en) 2007-12-04 2013-06-04 Novozymes A/S Protease variants for pharmaceutical use
JP2011508755A (ja) * 2008-01-03 2011-03-17 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 精製微生物リパーゼの顆粒を有する医薬組成物ならびに消化器疾患を予防又は治療する方法
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) * 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (en) * 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2328566A1 (en) * 2008-09-30 2011-06-08 DSM IP Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
WO2010080835A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
CA2747611C (en) 2009-01-06 2019-09-17 Curemark Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
RU2429291C1 (ru) * 2009-12-28 2011-09-20 Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) Пищеварительное средство на основе ферментов микробного происхождения
RU2012142134A (ru) * 2010-03-19 2014-04-27 Апталис Фарма Кэнэда Инк. Желудочно-резистентные ферментные фармацевтические композиции
UA111726C2 (uk) 2010-10-01 2016-06-10 Апталіс Фарма Лімітед Препарат панкреліпази низької сили з кишковорозчинним покриттям
US9816112B2 (en) 2010-12-22 2017-11-14 Novozymes A/S Processes for producing fermentation products
JP5976100B2 (ja) 2011-04-21 2016-08-23 キュアマーク リミテッド ライアビリティ カンパニー 神経精神障害の処置のための化合物
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
IN2014CN04905A (pt) * 2011-12-02 2015-09-18 Novozymes As
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
CA2884592C (en) 2012-09-19 2021-08-31 Grespo Ab Compositions for improvement of brain function
EP2996712B1 (en) 2013-03-15 2018-10-31 Allergan Pharmaceuticals International Limited Process for the preparation of a composition containing digestive enzymes and nutrients suitable for enteral administration
US11939552B2 (en) 2013-06-24 2024-03-26 Novozymes A/S Process of recovering oil
US10035973B2 (en) 2013-06-24 2018-07-31 Novozymes A/S Process of extracting oil from thin stillage
WO2015019198A2 (en) 2013-07-22 2015-02-12 Aptalis Pharma S.R.L. High potency pancreatin pharmaceutical compositions
MX2016001593A (es) 2013-08-09 2016-09-29 Allergan Pharmaceuticals Int Ltd Composicion de enzima digestiva adecuada para administracion enterica.
MX2016000480A (es) 2013-11-05 2016-10-21 Allergan Pharmaceuticals Int Ltd Composiciones farmaceuticas de pancreatina de alta potencia.
JP2017519490A (ja) 2014-06-19 2017-07-20 アプタリス ファルマ リミテッド 膵臓抽出物からのウイルス汚染の除去方法
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
WO2016126970A1 (en) 2015-02-04 2016-08-11 Abbvie Inc. Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
WO2019060851A1 (en) * 2017-09-24 2019-03-28 Bio-Cat, Inc. MIXTURES OF FUNGAL PROTEASE AND USES THEREOF
FR3079146B1 (fr) 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
FR3111559A1 (fr) * 2020-06-18 2021-12-24 Azurrx Biopharma, Inc. Formulations non porcines et leurs procédés
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1084431A (en) * 1964-05-06 1967-09-20 Analyses Et De Rech S Biolog M Improvements in and relating to lipases
DE2638088C3 (de) * 1976-08-24 1979-06-21 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verwendung von SuBmolkenpulver
JP3152958B2 (ja) * 1991-06-14 2001-04-03 天野エンザイム株式会社 微生物起源リパーゼの安定化組成物及び安定化法
DE4332985A1 (de) * 1993-09-28 1995-03-30 Konrad Peter Maria Dr Sommer Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament

Also Published As

Publication number Publication date
CN1236817C (zh) 2006-01-18
HUP0500560A3 (en) 2006-06-28
CN1487837A (zh) 2004-04-07
MXPA03005960A (es) 2003-09-05
RU2003124078A (ru) 2005-01-27
NO20033261L (no) 2003-07-18
EP1381386A2 (de) 2004-01-21
NZ527148A (en) 2005-01-28
IL157004A0 (en) 2004-02-08
HUP0500560A2 (hu) 2005-09-28
SK9292003A3 (en) 2003-12-02
CZ20031900A3 (cs) 2003-10-15
WO2002060474A3 (de) 2003-10-30
PL362646A1 (en) 2004-11-02
CA2434808A1 (en) 2002-08-08
NO20033261D0 (no) 2003-07-18
JP2004524838A (ja) 2004-08-19
AR032392A1 (es) 2003-11-05
US20040057944A1 (en) 2004-03-25
WO2002060474A2 (de) 2002-08-08

Similar Documents

Publication Publication Date Title
BR0206521A (pt) Misturas de enzimas microbianas
Thangam et al. Purification and characterization of alkaline protease from Alcaligenes faecalis
TR200102784T2 (tr) Diyabet tedavisi için ilaç
DE69825904D1 (de) Mutante alpha-amylase mit zusätzlicher disulfidverbindung
MXPA06001173A (es) Metodo analitico para la pancreatina y composiciones comparables.
TR200103216T2 (tr) Pirimidinon bileşimleri
NO20100214L (no) Preparat for a redusere LIPG ekspresjon hos en pasient og anvendelsen av dette
DK0544777T3 (da) Enzymatisk detergentsammensætning og fremgangsmåde til enzymstabilisering
DK39093D0 (da) Enzym
DK0938570T3 (da) Muteret alfa-amylase omfattende modifikation ved rester svarende til A210, H405 og/eller T412 i Bacillus licheniformis
DE3785036D1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
DE3872398D1 (de) Enzymatische waschmittelzusammensetzung.
ATE178945T1 (de) Enzymatische hydrolyse zur umwandlung von c7- zucker in c-7-hydroxyl-taxanen
WO2003061718A3 (en) Medical articles having enzymatic surfaces for localized therapy
ATE131066T1 (de) Mittel zur hemmung von hiv-proteasen.
EP0649472A4 (en) EUKARYOTIC CYTOCHROME P450 FUSION PROTEIN COUPLED TO A REDUCTASE.
FI921847A0 (fi) Farmaceutisk komposition som har endoproteolytisk aktivitet, foerfarande foer endoproteolytisk behandling av (prekursor)proteiner samt foerfarande foer (mikro)bio- logisk framstaellning av proteiner.
NO955258L (no) Medisinsk anvendelse av enzymer
ES2169036T3 (es) Dipeptidilaminopeptidasa de dictyostelium.
ATE222883T1 (de) Verwendung von mannanases als schleimkontrollmittel
ATE119780T1 (de) Katabolische enzyme zur induktion des tumornekrose-faktors (tnf).
ES2181897T3 (es) Composicion enzimatica.
KR890004724A (ko) 신규 프로테아제 제제(製劑)
DE60044038D1 (de) Xylosyltransferase und isoformen
BR9908966A (pt) Aplicação de lipase em fermentação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2055 DE 25/05/2010.